Velo3D, Inc. Form 8-K Summary
Business Context and Reporting Period
Velo3D, Inc. is an additive manufacturing and metal 3D-printing company. This Form 8-K reports board changes occurring in July 2023. The earliest reported event was July 25, 2023; the report was filed July 31, 2023.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Board appointment: Adrian Keppler was appointed to the Board effective August 1, 2023, filling the vacancy created by Ellen Pawlikowski’s resignation.
- Committee appointment: Dr. Keppler was also appointed to the Nominating and Governance Committee.
- Board term: He will serve as a Class I director with an initial term expiring at the Company’s 2025 annual meeting of stockholders.
- Board resignation: Gen. Ellen Pawlikowski resigned as a director and from the Board committees on which she served, effective July 31, 2023.
Outlook, Commentary, Risks, and Unusual Items
- Dr. Keppler is chief executive officer of AM Scalation and previously held senior leadership positions at EOS, a global 3D-printing solutions provider. He also serves in advisory or board roles with several additive manufacturing and related companies.
- The filing states that Gen. Pawlikowski’s resignation did not result from any disagreement with the Company or the Board.
- Dr. Keppler has no reported appointment arrangements or understandings and no transactions reportable under Item 404(a) of Regulation S-K.
- Dr. Keppler will receive compensation under the Company’s standard policy for non-employee directors and will enter into the Company’s standard indemnification agreement.
- The filing provides no financial guidance, operating outlook, contingency disclosures, or material risk updates.
Investor Verification Items
- Confirm the effective dates of Gen. Pawlikowski’s resignation and Dr. Keppler’s appointment.
- Review the Company’s director compensation policy and indemnification agreement for the economic terms applicable to Dr. Keppler.
- Assess any potential governance or competitive considerations arising from Dr. Keppler’s other board, advisory, and industry relationships.
- Review Exhibit 99.1, the related press release furnished with the filing.